Clinical Trial Update: Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial comparing subcutaneous and intravenous ACZ885 (canakinumab) in adults with established rheumatoid arthritis was conducted, and the study has b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ACZ885 (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: TERMINATED